



August 2, 2011

Safe Harbor Summary

This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Amyris's short-term and long-term growth, can sometimes be identified by use of terms such as "intend," "expect," "plan," "estimate," "future," "strive," and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in our Securities and Exchange Commission filings and reports, including the risks identified under the section captioned "Risk Factors" in our reports on Form 10-K filed on March 14, 2011 and on Form 10-Q filed on May 11, 2011. We disclaim any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris Highlights

1

Ramping
Commercial
Production



Biomin Producing
Antibióticos Operational
Tate & Lyle Q3

2

Expanding
Products and
Off-take

Firmenich



kuraray



3

Diesel Step Out



Accelerates Scale
Incremental Growth
Funding

1

Commercial Production Started



Amyris Production at Biomin operating as expected:

- Volumes in line with plan
- On track to meet 2011 targets

*First
Biofene™
production*



1

Additional Plants on Track: 2011



Antibioticos

León, Spain

Commencing Operations



Tate and Lyle

Decatur, IL

On Track for Q3 Operations




1

Additional Plants on Track: Paraíso

Paraíso

São Paulo state, Brazil

Target 1H 2012



1

São Martinho Amyris Plant On Plan



- To complete equipment purchases ~August 2011
- On target to complete foundation work ~November 2011
- Fermentor installation to start ~October 2011
- On plan for mid-2012 start-up


2

Expanding Product Offerings into Same Verticals

FINISHED PRODUCTS IN 6 VERTICALS

FERMENTATION

PROPRIETARY
BUILDING BLOCK



Farnesene (C15)

C10

ISOPRENE(C5)

Cosmetics



Flavors & Fragrance



Polymers & Plastic Additives



Lubricants



Consumer Products



Fuels



2

Alignment of Customers and Production: Supply Plan

CUSTOMERS/PARTNERS

PRODUCTION SOURCE



3 CMOs
(Biomin, T&L,
Antibióticos)



Paraiso



SMA

3

Emerging Agreement with Total on Diesel



- Validation of Amyris technology and diesel economics: expansion after extensive evaluation
- Agreement would provide current funding and establishment of JV to fund scale up and commercialize diesel
- Expect definitive agreements executed by year end; first dedicated plant operational 2013-2014

Amyris Key Strengths

Feedstock Access and Production

- Expect 5 current facilities to produce >200 million liters at target production efficiency
- Feedstock for expansion: 13 million tons under LOI/agreement

Strong Customer Demand

- Expect to be supply constrained
- Defined demand and customer agreements of \$2.5 billion exceed 2015 production plan
- Expect to begin filling this demand starting 2012

Significantly Expanding Growth Platform

- Diesel step out through Total JV
- Adding C5 and C10 molecules along with new customer agreements

2011 Outlook: Key Metrics


PRODUCTION VOLUME	6-9 MILLION LITERS
PRODUCTION COST	~\$3.70/LITER
ASP	\$6-\$7/LITER
Non-GAAP OpEx ⁽¹⁾	\$140-\$145 MILLION
NET CASH OpEx, Net of Partner Payments	\$70-80 MILLION
CapEx (with Paraiso)	\$75-\$90 MILLION

(1) GAAP Operating Expense outlook would also include ~\$25 million stock compensation expense


ROY 2011-2012 Cash Outlook

Key Assumptions: Cash Outlook dependent on achieving targets for OpEx, CapEx, Debt, Product Margin


Cash Balance



Cash Flow From Operations



Rest of Year Key Milestones



Production

Q3: Start up production at Tate & Lyle

Q3-4: SMA and Paraíso on schedule



Supply

Q3: Squalane and Diesel

Q4: Add Lubricant sales



Expansion

Isoprene collaboration and off-take

Total diesel JV

